(NOVO-B) Novo Nordisk - Ratings and Ratios

Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0062498333

Insulin, Hormones, Obesity Treatments, Injection Devices, Rare Disease Therapies

NOVO-B EPS (Earnings per Share)

EPS (Earnings per Share) of NOVO-B over the last years for every Quarter: "2020-03": 2.53, "2020-06": 2.27, "2020-09": 2.21, "2020-12": 2, "2021-03": 2.73, "2021-06": 2.63, "2021-09": 2.64, "2021-12": 2.38, "2022-03": 3.11, "2022-06": 2.93, "2022-09": 3.18, "2022-12": 3, "2023-03": 4.39, "2023-06": 4.31, "2023-09": 5.03, "2023-12": 4.93, "2024-03": 5.68, "2024-06": 4.49, "2024-09": 6.12,

NOVO-B Revenue

Revenue of NOVO-B over the last years for every Quarter: 2020-03: 33875, 2020-06: 30006, 2020-09: 30927, 2020-12: 32138, 2021-03: 33804, 2021-06: 33041, 2021-09: 35622, 2021-12: 38333, 2022-03: 42031, 2022-06: 41265, 2022-09: 45566, 2022-12: 48092, 2023-03: 53367, 2023-06: 54300, 2023-09: 58731, 2023-12: 65863, 2024-03: 65349, 2024-06: 68060, 2024-09: 71311,

Description: NOVO-B Novo Nordisk

Novo Nordisk A/S is a global pharmaceutical powerhouse with a presence in over 100 countries, specializing in the development and distribution of life-changing treatments for diabetes, obesity, and rare diseases. The companys Diabetes and Obesity Care segment is a leader in the industry, offering a range of innovative products, including insulin pens and smart insulin delivery systems, such as the NovoPen and Dose Check application. Additionally, the Rare Disease segment provides critical treatments for rare blood disorders, endocrine disorders, and hormone replacement therapy.

The companys commitment to innovation is evident in its collaborations with leading organizations, such as UNICEF, to address pressing global health issues like childhood obesity. Furthermore, its partnership with Valo Health, Inc. aims to discover and develop novel treatments for cardiometabolic diseases, expanding its portfolio and potential for growth. With a rich history dating back to 1923, Novo Nordisk A/S has established itself as a trusted and pioneering force in the pharmaceutical industry.

Analyzing the and , we can identify trends and insights that inform our forecast. The stocks current price is 453.65 DKK, with a 20-day SMA of 445.68 DKK and a 50-day SMA of 452.28 DKK, indicating a short-term uptrend. However, the 200-day SMA stands at 656.83 DKK, suggesting a longer-term downtrend. The ATR of 20.48 DKK (4.51%) indicates moderate volatility. Considering the companys strong RoE of 81.24% and a forward P/E of 16.08, we can anticipate a potential rebound in the stock price. Our forecast suggests that NOVO-B may experience a moderate increase in the coming months, driven by the companys innovative product pipeline and strategic partnerships, potentially reaching 550 DKK within the next 6-12 months.

To validate this forecast, we must continue to monitor the companys progress in its key segments, as well as any shifts in the global pharmaceutical landscape. By combining technical and fundamental analysis, we can refine our understanding of NOVO-Bs potential and make more informed investment decisions.

Additional Sources for NOVO-B Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

NOVO-B Stock Overview

Market Cap in USD 300,200m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Sub-Industry Biotechnology
IPO / Inception

NOVO-B Stock Ratings

Growth Rating 42.0
Fundamental 84.1
Dividend Rating 65.4
Rel. Strength -47.2
Analysts -
Fair Price Momentum 413.51 DKK
Fair Price DCF 297.74 DKK

NOVO-B Dividends

Dividend Yield 12m 2.11%
Yield on Cost 5y 5.64%
Annual Growth 5y 18.15%
Payout Consistency 88.5%
Payout Ratio 48.6%

NOVO-B Growth Ratios

Growth Correlation 3m 53.4%
Growth Correlation 12m -94.8%
Growth Correlation 5y 88.3%
CAGR 5y 16.90%
CAGR/Max DD 5y 0.28
Sharpe Ratio 12m -2.13
Alpha -65.32
Beta 0.757
Volatility 40.17%
Current Volume 3343.1k
Average Volume 20d 3346.9k
Stop Loss 423.1 (-3.6%)
What is the price of NOVO-B shares?
As of July 14, 2025, the stock is trading at DKK 438.95 with a total of 3,343,136 shares traded.
Over the past week, the price has changed by -0.51%, over one month by -14.97%, over three months by +0.71% and over the past year by -53.97%.
Is Novo Nordisk a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Novo Nordisk (CO:NOVO-B) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.14 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NOVO-B is around 413.51 DKK . This means that NOVO-B is currently overvalued and has a potential downside of -5.8%.
Is NOVO-B a buy, sell or hold?
Novo Nordisk has no consensus analysts rating.
What are the forecasts for NOVO-B share price target?
According to our own proprietary Forecast Model, NOVO-B Novo Nordisk will be worth about 473.6 in July 2026. The stock is currently trading at 438.95. This means that the stock has a potential upside of +7.88%.
Issuer Target Up/Down from current
Wallstreet Target Price 645.2 47%
Analysts Target Price - -
ValueRay Target Price 473.6 7.9%